Sentio
Wixom
About Sentio
Sentio MMG® is a surgical access tool. It is intended to locate and map motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2. Sentio MMG® smart-sensors are different from all other forms of neuromonitoring electrodes. In contrast to electromyography, or EMG, which relies on needles to detect subtle changes in electrical signals in muscle, Sentio MMG® smart-sensors employ proprietary accelerometer technology. These non-invasive accelerometer-based sensors measure MMG (mechanomyography) activity, or the mechanical “twitch” associated with muscle contraction. When MMG activity is detected, the surgeon is provided with a ‘STOP’ alert indicating a nerve has been identified. The result is an intuitive, surgeon-directed tool for establishing safe access in a variety of surgical applications. Sentio MMG® was specifically designed to facilitate safe lateral transpsoas surgery. Sentio believed there was a better way to identify and map nerves during lateral surgery that did not require EMG. Design objectives included:
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: M&A
- Last round: Seed (May 2010)
- Website: sentiommg.com
- Phone: +1 248 595-0420
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/sentio-1712199 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.